Journal of Alzheimer's Disease

Startpagina
Nederland
Amsterdam
Journal of Alzheimer's Disease

An international multidisciplinary journal The journal publishes research reports, reviews, short communications, book reviews, and letters-to-the-editor.

JAD is an international multidisciplinary journal to facilitate progress in understanding the etiology, pathogenesis, epidemiology, genetics, behavior, treatment and psychology of Alzheimer’s disease. The journal is dedicated to providing an open forum for original research that will expedite our fundamental understanding of Alzheimer’s disease. Editor-in-Chief
George Perry, PhD
University of Texa

s at San Antonio
USA
Tel: +1.210.458.8660
Fax:+1.210.458.5658
Email: [email protected]
ORCID iD: 0000-0002-6547-0172

To view the full list of the Editorial Board, please visit: http://j-alz.com/board. JAD is a member of the Neuroscience Peer Review Consortium (http://nprc.incf.org). The Consortium is an alliance of neuroscience journals that have agreed to accept manuscript reviews from each other. Abstracting/Indexing

Biological Abstracts
BIOSIS Previews
CAB Abstracts
CAB Health
Chemical Abstracts Service (CAS)
CSA Biological Sciences
CSA Illumina
CSA Illustrata Natural Sciences
CSA Neurosciences Abstracts
e-psyche database
EBSCO database
Embase
EMCare
Index Copernicus
Index Medicus
Journal Citation Reports/Science Edition
MEDLINE
Neuroscience Citation Index
Prous Science Integrity
PsycInfo
PubMed
PubsHub
Science Citation Index Expanded (SciSearch)
Scopus

Audience

JAD's targeted audience is comprised of basic science researchers and clinicians in the areas of Alzheimer's disease and related disorders.

21/06/2026

High-dose omega-3 supplements reach the brain but offer no cognitive benefits in older adults at high-risk for Alzheimer’s disease, a new trial suggests.

19/06/2026

Doctor-patient conversations may hold clues to cognitive impairment

19/06/2026

A novel PET imaging agent identified AD-related tau earlier and in more patients than the currently used tracer, possibly speeding AD detection, a new study shows.

19/06/2026

Alzheimer’s disease pathology, measured by amyloid and tau blood biomarkers, can appear in midlife and is associated with worse cognitive performance years before dementia onset.

19/06/2026

Dementia is associated with increased risk for suicidal behavior, with younger patients and men with dementia at even greater risk, a new meta-analysis shows.

19/06/2026

Two-way relationships with traumatic brain injury emerge in a large study of veterans

19/06/2026

📗 NEW ISSUE! This edition features Review articles on:

Unmet social needs of community-living older adults with dementia: A scoping review, by Tan et al.

Attitudes of older adults toward active euthanasia in advanced Alzheimer's disease, by Kermel-Schiffman et al.

Explore these articles and more: https://journals.sagepub.com/toc/alza/111/4

Table of contents for Journal of Alzheimer’s Disease, 111, 4

17/06/2026

Blood Tests for Alzheimer’s: Progress, Limitations and the Road Ahead

17/06/2026

💡 New study published in JAD finds that routine retinal photos can be used to flag Alzheimer's risk factors years before symptoms appear, offering new opportunities to identify at-risk patients and intervene before irreversible damage to the brain takes place.

Read more in University of Florida News: https://news.ufl.edu/2026/06/alzheimer-retina/

Read the article in JAD: https://journals.sagepub.com/doi/10.1177/13872877261457650

Routine retinal photos, already common in eye exams, can be used to flag risk factors linked to Alzheimer’s years before symptoms appear.

17/06/2026

BackgroundAdvanced Alzheimer’s disease (AD) is generally regarded as a stage of irreversible functional decline. Psilocybin is known to transiently alter lar...

Adres

Nieuwe Hemweg 6B
Amsterdam
1013BG

Telefoon

+31 20 688 3355

Website

http://j-alz.com/

Meldingen

Wees de eerste die het weet en laat ons u een e-mail sturen wanneer Journal of Alzheimer's Disease nieuws en promoties plaatst. Uw e-mailadres wordt niet voor andere doeleinden gebruikt en u kunt zich op elk gewenst moment afmelden.